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Primary HIV-1 infection is characterized by extremelyThe Johns Hopkins University School of Medicine
Baltimore, Maryland 21205 high levels of plasma virus (Daar et al., 1991). Values in
excess of 106 copies of RNA/ml are commonly seen. As
the immune response to HIV-1 develops, plasma virus
levels fall to lower steady-state values that vary in differ-A great deal of progress has been made in understand-
ent individuals and that are predictive of the rate ofing the molecular biology of HIV-1 replication (see re-
disease progression (Mellors et al., 1996). In untreatedviews by Cullen [1998], Chan and Kim [1998], and Litt-
asymptomatic patients, the plasma HIV-1 RNA levelsman [1998] in this issue of Cell). Nevertheless, critical
are typically in the range of 103±106 copies/ml in blood.aspects of AIDS pathogenesis remain to be elucidated.
Titers of infectious virus are several orders of magnitudeFor example, it is still unclear how HIV-1 infection in-
lower, indicating that much of this plasma virus is defec-duces CD41 T cell depletion, which is the central patho-
tive, decayed, or neutralized.physiologic feature of the disease. It is also uncertain
During the asymptomatic phase of the infection, thehow the virus persists in the presence of vigorous im-
level of plasma HIV-1 RNA is reasonably stable in a givenmune responses.Recently, important insights into these
individual in the short run (days to weeks). This reflectscomplex aspects of the host±pathogen interaction in
a quasi±steady state in which virus production equalsHIV-1 infection have come from a surprisingly simple
virus clearance. The equilibrium has been formalized byapproach, the direct measurement of circulating levels
Perelson and colleagues in the form of the equation P 5of free virus. The development of rapid, sensitive, and
cV where P is the viral production rate, c is the viralaccurate methods for quantitating virus particles in the
clearance rate constant, and V is the number of plasmablood has greatly facilitated thestudy of AIDS pathogen-
virions (Ho et al., 1995; Perelson et al., 1996, 1997a).esis and the management of patients with HIV-1 infec-
At a first approximation, the dynamics underlying thistion. Quantitative competitive RT-PCR is carried out on
equilibrium between virus production and virus clear-blood and other biological fluids to detect genomic viral
ance can be represented as:RNA, which is present at two copies per virion (Piatak
et al., 1993). Because the rate of clearance of free virus
dV/dt 5 NdT* 2 cV
from the blood is largely independent of stage of disease
and other factors, the level of viral RNA in the plasma in which NdT*, the virus production term, is the product
reflects the rate of virus production. Recent studies sug- of the number of new virions produced per infected cell
gest that the half-life of free virus particles is extremely (N), the rate of loss of productively infected cells (d), and
short, on the order of minutes to hours (Perelson et al., the number of productively infected cells (T*). At steady
1996). Thus, the steady-state level of viral RNA genomes state, dV/dt 5 0 and NdT* 5 cV. As is discussed below,
in the blood reflects very recent virus production. As a perturbation of this equilibrium by treatment with antiret-
result, physicians and investigators in this field have a roviral drugs has given important information about the
tool that is available for few other infectious diseases, rates of virus production and the rates of clearance of
a real-time measure of the rate of replication of the free virus particles (c) and of productively infected cells
pathogen in the host. Analysis of dynamic changes in (d). Perelson et al. have also constructed more elaborate
the level of plasma virus at different stages of disease models that take into account virus production by differ-
and in response to antiretroviral therapy has provided ent cell types with different rates of clearance. These
some startling new insights into the mechanism of CD41 models have proven very useful in the analysis of viral
T cell depletion, the reasons for drug failure, the nature reservoirs in infected individuals (Perelson et al., 1996,
of viral reservoirs, and the intriguing possibility that pro- 1997a). Before considering these models of viral dynam-
longed therapy may lead to virus eradication. The mea- ics, it is worth reviewing in a qualitative sense where
surement of viral dynamics in vivo is a new area of study, the plasma virus comes from and what happens to it.
made possible by the availability of assays for free virus Current evidence favors the idea that most of the
and of antiretroviral drugs that perturb the steady-state plasma virus comes from recently infected CD41 lym-
equilibrium between virus production and virus clear- phoblasts in the peripheral lymphoid tissues. The infec-
ance. It is likely that lessons learned will have broad- tion of CD41 T cells by HIV-1 is best considered in the
reaching influence on the study of other infectious dis- context of the normal physiology of T cell activation
eases. This review will discuss recent advances in the (Figure 1). Uninfected CD41 T cells emerge from the
study of viral dynamics, focusing on the possibility of thymus as naive cells and circulate until they encounter
HIV-1 eradication with antiretroviral therapy. antigen. They then undergo blast transformation and
begin to proliferate. Some of the cells survive and return
to a G0 resting state in which they persist as memoryThe Steady State
One important and incontrovertible principle to emerge cells able to respond again to subsequent encounters
with the same antigen. Memory T cells are distinguish-from measurements of plasma virus levels inHIV-1 infec-
tion is that viral replication continues throughout the able from naõÈve cells based on differential expression
of adhesion molecules and altered triggering thresholds.disease, even during the prolonged asymptomatic phase
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Figure 1. Cellular Dynamics of HIV-1 Infec-
tion of CD41 T Cells
Successive steps in the life cycle of the virus
are indicated by horizontal arrows. Transi-
tions between resting (small) and activated
(large) CD41 T cells are illustrated by vertical
arrows. X4 isolates of HIV-1 can infect resting
and activated CD41 T cells, but replication
does not occur in resting cells due to a block
prior to the stage of nuclear import of the
preintegration complex containing the re-
verse transcribed HIV-1 DNA. R5 isolates can
infect activated CD41 T cells, but may infect
only the subset of resting CD41 T cells that
express sufficient amounts of CCR5. Note
that resting cells with unintegrated HIV-1 DNA
are likely to represent a relatively labile reser-
voir for the virus (preintegration latency). Pro-
ductive infection requires antigen-driven acti-
vation of recently infected resting CD41 cells
or, more commonly, direct infection of anti-
gen-activated CD41 T cells. Productively in-
fected cells generally die within a few days
from cytopathic effects of the infection or host cytolytic effector mechanisms, but some infected lymphoblasts survive long enough to go
back to a resting state, thereby establishing a stable latent reservoir of resting memory CD41 T cells with integrated HIV-1 DNA (postintegration
latency).
T cell tropic (X4) HIV-1 isolates can infect CD41 T cells individual, most T cells at any given time are in a resting
state, with an approximately equal fraction of cells inin all of these stages. Macrophage tropic (R5) HIV-1
isolates can infect activated CD41 T cells but may not the naõÈve and memory pools. In infected individuals, the
proportion of activated cells increases. The fraction ofinfect resting cells readily because of the low expression
of CCR5. In any event, the infection does not progress CD41 T cells that are infected has been controversial,
but recent evidence suggests that for both resting andin resting cells due to a block prior to the stage of
nuclear import of the preintegration complex containing activated CD41 T cells, the fraction of cells with stably
integrated, replication-competent provirus is very smallthe reverse transcribed HIV-1 DNA. Resting cells with
unintegrated HIV-1 DNA may represent a latent reservoir (,0.1%) (Chun et al., 1997a). Among resting CD41 T
cells, a higher fraction of cells (1%) may harbor uninte-for the virus in the sense that if these cells are activated
by antigen before the preintegration complex decays, grated HIV-1 DNA (Bukrinsky et al., 1991; Chun et al.,
1997a).then the subsequent steps of nuclear import, integra-
tion, virus gene expression and virus production occur The dynamics of infection are somewhat different in
the case of cells of the monocyte-macrophage lineage,(Zack et al., 1990; Bukrinsky et al., 1991, 1992; Spina et
al., 1995). The major pathway to productive infection the other major cell lineage that is susceptible to infec-
tion in vivo (Ho et al., 1986; Gartner et al., 1986; Nicolsonprobably involves direct infection of activated CD41 T
cells. These infected lymphoblasts arehighly permissive et al., 1986). Circulating monocytes, the precursors of
tissue macrophages, do not show a significant levelfor viral replication and rapidly begin to produce virus.
However, infected CD41 lymphoblasts die quickly (t1¤2 z of infection as assessed by DNA PCR, indicating that
infection may occur after the monocytes have left the1 day, see below) due to viral cytopathic effects and/or
host cytolytic effector mechanisms. A small fraction of circulation and differentiated into macrophages (Schnitt-
man et al., 1989). In in vitro infections, macrophages dothe productively infected cells may survive long enough
to revert back to a resting memory state in much the not succumb to the cytopathic effects of HIV-1 infection.
This observation has led to the suggestion that infectedsame way that noninfected CD41 lymphoblasts do. The
resulting memory cells carry an integrated copy of the macrophages may represent a major reservoir for the
virus in vivo. As is the case with CD41 T cells, only aHIV-1 genome. Because of the absence of activation-
dependent host transcription factors and insufficient minute fraction of the macrophage pool carry integrated
provirus at any given time (Chun et al., 1997a). Macro-levels of positive regulatory viral factors such as tat
and rev, the integrated provirus in resting memory cells phages play an important role in the presentation of
antigens to CD41 T cells, and it is possible that infectedremains latent until the memory cell is reactivated by
antigen (Folks et al., 1989; Pomerantz et al., 1990, 1992; macrophages may transmit the infection to CD41 T cells
during antigen presentation. The same is true of boneGarcia-Blanco and Cullen,1991; Seshamma et al., 1992).
These resting memory cells thus represent a second marrow±derived dendritic cells, which are highly spe-
cialized for antigen presentation (Cameron et al., 1992;type of latent reservoir for HIV-1, one with a great poten-
tial for stability resulting from the integrated nature of Pope et al., 1994). The frequency and half-life of infected
dendritic cells in vivo is unknown.the latent provirus and the long life span of the memory
cells harboring the latent provirus. The major site of virus replication appears to be in
the peripheral lymphoid organs, such as the lymphIt is also important to appreciate the pool sizes of the
different cells represented in Figure 1. In an uninfected nodes and the spleen, and in the mucosal lymphoid
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tissue (Pantaleo et al., 1991, 1993; Embretson et al.,
1993; Frankel et al., 1996; Veazey et al., 1998). Pivotal
early studies of lymph node biopsies from infected indi-
viduals demonstrated that the fraction of lymphoid cells
that were infected with HIV-1 was higher in the lymph
nodes than in theperipheral blood. This finding, together
with the fact that the vast majority (98%) of lymphocytes
are located in the peripheral lymphoid tissues, has given
rise to the idea that these tissues are the major site of
virus replication. Some of the virus produced within the
lymph nodes is trapped on a specialized cell type known
as a follicular dendritic cell (FDC), which is distinct from
Figure 2. Hypothetical Decay Curve for Plasma Virus Levels in athe bone marrow±derived dendritic cell described above
Patient Treated with Highly Active Antiretroviral Therapy (HAART)(Pantaleo et al., 1993). FDCs are located in the germinal
The t1¤2 for the first phase of decay is based in the work of Shaw andcenters of the secondary lymphoid organs where they
Ho and their colleagues (Wei et al., 1995; Ho et al., 1995; Perelson et
function to bind and present intact antigens to Blympho- al., 1996, 1997a). The t1¤2 of the second phase of decay is based on
cytes. FDCs express Fcg and complement receptors the work of Perelson et al. (1997a). The existence of a putative third
that facilitate the trapping of immune complexes. In in- phase of decay, reflecting the extremely slow turnover of a small
number of latently infected resting CD41 T cells, is suggested.fected individuals, virus particles that have reacted with
anti-envelope antibodies may be trapped on FDCs cre-
ating a major potential reservoir. There is some evidence without preventing virus production by cells that have
for retention of infectivity despite the coating of the already been infected. The rapid, exponential decline
virion with antibody and complement that is necessary observed in treated patients was taken as evidence that
for attachment to FDCs (Heath et al., 1995). The FDC the drugs largely prevent any new infection of suscepti-
network is disrupted late in the course of disease at ble cells. In this situation, the observed decreases in
a time when the concentration of plasma virus rises plasma virus levels reflect the intrinsic decay rates of
(Pantaleo et al., 1993). Increases in plasma virus may the various cellular and extracellular compartments that
reflect the loss of the trapping function of FDC. Virions harbor virus.
that are produced in the lymph nodes and fail to bind In a subsequent study, Perelson and colleagues ex-
to FDC can escape and enter the circulation. amined plasma viral levels early after the initiation of
To summarize, the prolonged asymptomatic phase of therapy in an effort to measure separately the two pro-
HIV-1 infection is characterized by a steady state in cesses that contribute to the rapid initial decay of
which continuous virus production is balanced by virus plasma virus: the clearance of free virions and the loss
clearance. Most of the plasma virus is produced by of the infected cells that produce most of the plasma
infected CD41 lymphoblasts in the peripheral lymphoid virus (Perelson et al., 1996). This was done by solving
tissues. Mechanisms of virus clearance remain unclear. a set of differential equations describing the dynamics
A much better understanding of the dynamics of HIV-1 of cell infection and virion production and by fitting the
infection was achieved when antiretroviral drugs were decay data to the derived model. In this way, the decay
used to perturb this steady state. rate constants for free virus (c) and for the cells that
produce most of the plasma virus (d) were calculated.
The resulting values for c were strikingly similar in differ-
The First Phase of Decay ent patients, consistent with the idea that c is an intrinsic
In 1995 the laboratories of GeorgeShaw at the University decay rate of a particular compartment. The same was
of Alabama and David Ho at the Aaron Diamond AIDS true for d. Mean values for c and d were 3 and 0.5
Research Center published profoundly influential pa- day21, respectively. These rate constants are most easily
pers describing the effects of potent new inhibitors of evaluated in the form of half-lives (t1¤2 5 ln2/c, ln2/d). For
HIV-1 reverse transcriptase and protease on plasma vi- free virus, t1¤2 was ,6 hr. For productively infected cells,
remia in HIV-1-infected patients (Wei et al., 1995; Ho et t1¤2 was z1±2 days. Direct confirmation of the rapid turn-
al., 1995). These papers not only changed the course over of productively infected cells has been provided
of AIDS therapy but also provided critical insights into by Haase and colleagues using insitu hybridization anal-
the pathogenesis of the disease. The critical finding was ysis of tonsillar biopsies from patients starting antiret-
that potent antiretroviral drugs produced a very rapid roviral therapy (Cavert et al., 1997). The lability of both
exponential drop in the level of plasma virus. Typically, the plasma virus and the cells that produce most of the
plasma virus levels decreased 100-fold in two weeks plasma virus underscores the fact that virus replication
(Figure 2).Analysis of this rapid decline led to the conclu- is active and ongoing throughout the course of the dis-
sion that HIV-1 infection isa dynamic process character- ease. HIV-1 is cytopathic for CD41 T cells, and it is
ized by continual new rounds of viral infection of and likely that the short-lived cells that produce most of the
replication in susceptible cells. Most of the plasma virus plasma virus are CD41 T lymphoblasts. A corollary is
is produced by recently infected cells. Neither the free that long-lived infected cells such as macrophages and
virus nor the cells that produce most of the plasma virus latently infected T cells must make only a minor contri-
survive very long. It is important to recall that both the bution to plasma viremia in untreated patients.
reverse transcriptase inhibitors and the protease inhibi- Measurement of the viral clearance rate c allows cal-
culation of P, the rate of virus production, using thetors act to prevent new infection of susceptible cells
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equation P 5 cV. Figures in excess of 1010 virions per studies showed that combinations of antiretroviral agents
could produce a decline in plasma virus to undetectableday have been reported (Perelson et al., 1996). The high
levels in many patients (Gulick et al., 1997; Perelson etlevels of virus produced per day are instructive inseveral
al., 1997a). Careful studies by Perelson et al. showedregards (see Coffin, 1995). The high rate of virus produc-
that, after the rapid initial decay during the first 1±2tion, when considered in the context of the short half-
weeks of treatment, plasma virus declined at a slowerlife of cells that produce most of the plasma virus, sug-
rate, reflecting the turnover of a longer-lived viral reser-gests that the rate of new infection of CD41 T cells
voir or infected cell population (Figure 2). This reservoiris substantial. Uncertainty over the number of virions
accounts for only a small portion of the total virus pro-produced per infected cell (the burst size, N) makes it
duction in an untreated individual and becomes evidentdifficult to calculate precisely the number of produc-
only when the cells that produce most of the plasmatively infected cells (T*) from the steady-state relation-
virus have largely decayed. The half-life of the compart-ship NdT* 5 cV. However, Haase and colleagues have
ment responsible for this second phase of decay wasestimated T* by using in situ hybridization to detect cells
estimated to be 1±4 weeks (Perelson et al., 1997a). Aexpressing HIV-RNA in the lymphoid tissue (Haase et
biphasic decay process was also observed directly inal., 1996). The total body value obtained, 4 3 107 cells,
in situ hybridization studies of productively infected mo-was in good agreement with estimates based on quanti-
nonuclear cells in the lymphoid tissues (Cavert et al.,tation of integrated HIV-1 DNA in activated CD41 T cells
1997).in the lymph nodes (Chun et al., 1997a). Because of the
In many patients on highly active antiretroviral therapytechnical difficulties involved, these approaches may
(HAART), the second phase of decay brings levels ofunderestimate the number of productively infected CD41
plasma virus down to below the limit of detection ofT cells. Nevertheless, it is clear that in an untreated
current assays (20±500 copies/ml). Perelson et al. havepatient, large numbers of CD41 T cells become infected
used the careful analysis of second phase decay ratesdaily. The reverse transcription process that occurs in
to make the first rational predictions of treatment timeseach of those newly infected cells has a sufficiently high
required for virus eradication, with the caveat that thereerror rate that viral genomes with every possible single
may be undetected compartments or viral reservoirspoint mutation arise daily (Coffin, 1995). Perelson and
that are not measurable by standard techniques (Perel-
colleagues have estimated that if 108 new cells are in-
son et al., 1997a). If it is assumed that there are no
fected per day, then not only are all possible single point
additional reservoirs, the second phase of decay extrap-
mutations generated daily, but almost 1% of all possible
olates to zero residual infected cells in 2±3 years of
double mutations are generated each day (Perelson et
completely suppressive antiretroviral therapy.
al., 1997b). This finding has enormous implications for
The nature of the viral reservoir that is responsible for
understanding the evolution of drug resistance muta- producing most of the plasma virus during this second
tions and viral escape from immune effector mecha- phase is unclear. One idea is that this virus is derived
nisms. from infected macrophages that turn over much more
The high rate of virus production also has implications slowly than infected CD41 lymphoblasts (Perelson et
for the debate over mechanisms of CD41 T cell deple- al., 1997a). The observed decay rate is compatible with
tion. Whether the direct killing of HIV-1-infected CD41 measured rates for the turnover of macrophages in unin-
T cells is the cause of CD41 T cell depletion has been fected individuals. It remains unclear whether the num-
a central issue in AIDS research. The characteristics ber of macrophages infected in vivo is sufficient to ac-
of the first phase of decay suggest that productively count for the requisite level of virus production during
infected cells die quickly, but it has been unclear the second phase. Virions trapped on FDC also decline
whether this effect alone is sufficient to account for in this time scale in individuals treated with HAART (Ca-
CD41 T cell depletion. A major problem is the absolute vert et al., 1997).
number of CD41 T cells that die per day from infection
is still unknown. The increase in CD41 T cell counts The Third Phase of Decay
following initiation of HAART therapy is undoubtedly due Despite the dramatic success of HAART in reducing
in part to a decrease in virus-induced cell killing, but plasma viremia to undetectable levels in some patients,
quantitative analysis of CD41 T cell reconstitution is there has been the concern that the infection will be
complicated by the fact that early increases in CD4 ªrekindledº if therapy is withdrawn. In patients who ex-
counts may reflect a redistribution of CD41 T cells from periencecomplete suppression of new cycles of replica-
the secondary lymphoid organs with a late component tion for the estimated 2±3 years required for the second
of increased production of naõÈve cells (Autran et al., phase of decay to be complete, the residual virus that
1997). Additional factors to be considered include the would rekindle the infection could only come from a
possibility that CD4 depletion is due to effects on thy- compartment with the following two characteristics.
mopoeisis (Rabin et al., 1995; Su et al., 1995) or to indi- First, this compartment would have to be extremely sta-
rect effects on uninfected CD41 T cells (Banda et al., ble. Second, it would have to be responsible for produc-
1992; Finkel et al., 1995). An excellent review of these ingonly a minute fraction of theplasma virus inuntreated
complex issues has recently been published (Hellerstein individuals since the cells that produce most of the
and McCune, 1997). plasma virus decay quickly. As shown in Figure 2, the
existence of such a compartment cannot be ascertained
The Second Phase of Decay from the measurement of plasma HIV-1 RNA levels be-
Although drug resistance developed rapidly in patients cause of the difficulties involved in quantitating ex-
tremely low levels of plasma virus. Therefore alternativetreated with protease inhibitors as monotherapy, further
Review
669
approaches are needed to demonstrate the existence
of compartments responsible for a putative third phase
of decay.
Several recent studies suggest that latently infected
resting memory CD41 T cells with integrated provirus
represent an extremely stable reservoir for HIV-1 that
may be responsible for the third phase of decay in pa-
tients on HAART (Chun et al., 1995, 1997a, 1997b; Finzi
et al., 1997; Wong et al., 1997b). The importance of
this reservoir derives from a fundamental aspect of the
biology of memory cells; these cells must survive for
long periods of time in order to provide protection
against previously encountered pathogens. Although it
has been presumed that the integration of HIV-1 DNA
into the genomesof infected CD41 T lymphocytes allows
viral persistence, there has been until recently little di-
rect evidence that resting memory CD41 T cells with
Figure 3. Estimated Half-Lives of Cellular and Extracellular Com-integrated provirus function as a latent reservoir for
partments Harboring HIV-1HIV-1 in infected individuals. Transformed cell lines car-
The half-life of free virions is ,6 hr, based on the work of Perelsonrying integrated HIV-1 DNA have been used to model
et al. (1996). The half-life of the cells that produce most of theplasma
latent infection (Folks et al., 1989; Pomerantz et al.,1990) virus was measured by Wei et al. (1995) and by Ho and colleagues
and have provided a great deal of information about (Ho et al., 1995; Perelson et al., 1996, 1997a). The most recent
estimates suggest a half-life of 1 day. The stability of the uninte-the molecular mechanisms involved in the regulation
grated HIV-1 DNA in resting CD41 T cells is still uncertain. Rescueof HIV-1 gene expression. Direct evidence of proviral
of infectious virus can be achieved by activation of the cells, andlatency in vivo came from inverse PCR studies showing
some studies have noted a loss in the ability to rescue virus after
the presence of integrated HIV-1 DNA in extremely pure several days in culture (Zack et al., 1988; Chun et al., 1997a). Failure
populations of resting CD41 T cells isolated from in- to rescue infectious virus from infected resting cells could reflect
fected donors (Chun et al., 1995). The frequencies of degradation of unintegrated HIV-1 DNA or loss of some essential
protein components of the preintegration complex. In other studies,such cells with integrated HIV-1 DNA were extremely low
the intermediates that formed following in vitro infection of resting(,0.05%) and were similar in blood and lymph nodes,
CD41 T cells showed greater stability (Spina et al., 1995). Analysisconsistent with the continual recirculation of memory
of this issue is complicated by the fact that resting CD41 T cells do
cells. The frequencies did not correlate with CD4 count, not survive in vitro for more than 2±3 weeks. The pool of extracellular
plasma RNA, or therapy (Chun et al., 1997a). Those find- virions bound to FDC shows a biphasic decay with a rapid initial
ings suggested that, in asymptomatic HIV-1 infection, phase (t1¤2 5 1.7 days) followed by a second slower phase of decay
(t1¤2 5 14 days) (Cavert et al., 1997). The half-life of infected macro-a relatively stable systemic steady state is established
phages remains a critical unknown. Perelson et al. (1997a) havein which only a minute fraction of the resting CD41 T cell
suggested that these cells may be responsible for the second phase
population carries integrated HIV-1 DNA (Coffin, 1995; of decay (t1¤2 5 14 days). This rate of turnover would be consistent
Chun et al., 1997a). The total body number of resting with that observed for macrophages in uninfected individuals (Van
CD41 T cells with integrated HIV-1 DNA was estimated Furth, 1989). However, it must be kept in mind that the rate of
macrophage turnover may depend upon the tissue and may beto be approximately 107 cells, only a fraction of which
influenced by HIV-1 infection. Finally, the rate of turnover of latentlycarry replication-competent provirus. Among resting
infected resting CD41 T cells with integrated HIV-1 DNA is unknown.CD41 T cells, integrated HIV-1 DNA was present primar-
In initial cross-sectional studies of patients on HAART, no significant
ily among cells with a CD45RO1 phenotype, characteris- decay is apparent in the first 2 years of therapy (Finzi et al., 1997).
tic of memory cells (Chun et al., 1997a). For theoretical reasons discussed in the text, it is possible that the
half-life of this compartment may be even longer than that averageAlthough several studies have noted that amplifiable
half-life of resting memory CD41 T cells. In uninfected individuals,HIV-1 DNA persists in the cells of patients on long-term
these cells have a mean intermitotic interval of 5.5 months (McLeanHAART (Perelson et al., 1997a; Cavert et al., 1997; Wong
and Michie, 1995).
et al., 1997a), it has often been presumed that the provi-
ral DNA burden in T cells represents mainly defective
archival sequences. In fact, it is often difficult to isolate in a latent form in resting CD41 T cells raises the possibil-
HIV-1 from T cells of patients on long-term HAART using ity that this reservoir might represent a major barrier to
conventional virus culture methods. However, with en- virus eradication in patients on HAART.
hanced virus culture conditions designed to induce uni- Three recent studies examined whether replication-
form activation of resting CD41 T cells, replication-com- competent virus could persist in the resting CD41 T cells
petent virus can be recovered from highly purified of patients on HAART (Finzi et al., 1997; Wong et al.,
resting CD41 T cells (Chun et al., 1997a). The frequencies 1997b; Chun et al., 1997b). These studies focused on a
of resting CD41 T cells with replication-competent provi- subset of patients who responded extremely well to
rus are lower than the frequencies of resting CD41 T therapy and who had been aviremic for as long as 2.5
cells with integrated HIV-1 DNA (as detected by inverse years. Although it is generally very difficult to isolate
PCR). This suggests that some of the integrated HIV-1 virus from patients on long term HAART by conventional
DNA in resting CD41 T cells is defective. Nonetheless, methods, all three groups found that with enhanced
culture techniques, replication-competent virus couldthe finding that replication-competent virus can persist
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import of human immunodeficiency virus type 1 preintegration com-be readily isolated from resting CD41 lymphocytes of
plexes. Proc. Natl. Acad. Sci. USA 89, 6580±6584.these patients. Most importantly, in cross-sectional
Cameron, P.U., Freudenthal, P.S., Barker, J.M., Gezelter, S., Inaba,analysis, the frequencies of latently infected CD41 T
K., and Steinman, R.M. (1992). Dendritic cells exposed to humancells showed no detectable decrease during the first
immunodeficiency virus Type-1 transmit a vigorous cytopathic in-
two years of therapy (Finzi et al., 1997). This is in marked fection to CD41 T cells. Science 257, 383±387.
contrast to other viral reservoirs examined to date, all Cavert, W., Notermans, D.W., Staskus, K., Wietgrefe, S.W., Zupan-
of which show readily measurable decay rates (Figure cic, M., Gebhard, K., Henry, K., Zhang, S.-C., Mills, R., McDade, H.,
3). These results suggest an extremely slow decay rate et al. (1997). Kinetics of response in lymphoid tissue to antiretroviral
therapy of HIV-1 infection. Science 276, 960±964.for this compartment, consistent with the long-term
Chan, D.C., and Kim, P.S. (1998). Cell 93, this issue, 681±684.survival of resting memory CD41 T cells in uninfected
Chun, T.-W., Finzi, D., Margolick, J., Chadwich, K., Schwartz, D.,individuals (mean intermitotic interval 5 5.5 months;
and Siliciano, R.F. (1995). Fate of HIV-1-infected T cells in vivo: ratesMcLean and Michie, 1995). At the present time, it is
of transition to stable latency. Nat. Med. 1, 1284±1290.unclear whether the extraordinary stability of this com-
Chun, T.-W., Carruth, L., Finzi, D., Shen, X., Digiuseppe, J.A., Taylor,partment is due to the long life span of latently infected
H., Hermankova, M., Chadwick, K., Margolick, J., Quinn, T.C., et al.
memory cells or to replenishment of the compartment (1997a). Quantitation of latent tissue reservoirs and total body load
by very low levels of ongoing viral replication. Sequence in HIV-1 infection. Nature 387, 183±188.
analysis of viruses isolated from this compartment re- Chun, T.W., Stuyver, L., Mizell, S.B., Ehler, L.A., Mican, J.M., Baseler,
vealed little evidence for the evolution of drug resis- M., Lloyd, A.L., Nowak, M.A., and Fauci, A.S. (1997b). Presence of
an inducible HIV-1 latent reservoir during highly active antiretroviraltance, suggesting that the viruses that persist in this
therapy. Proc. Natl. Acad. Sci. USA 94, 13193±13197.compartment are derived from long-lived cells infected
Coffin, J.M. (1995). HIV population dynamics in vivo: implications forprior to the initiation of HAART (Finzi et al., 1997; Wong
genetic variation, pathogenesis, and therapy. Science 267, 483±489.et al., 1997b). One critical factor in determining how
Coombs, R.W., Collier, A.C., Allain, J.-P., Nikora, B., Leuther, M.,long a latently infected memory cell will persist in this
Gjerset, G.F., and Corey, L. (1989). Plasma viremia in human immu-compartment is the frequency with which the relevant
nodeficiency virus infection. N. Engl. J. Med. 321, 1626±1631.
antigen is encountered. Latently infected CD41 T cells
Cullen, B.R. (1998). Cell 93, this issue, 685±692.
specific for frequently encountered antigens may be
Daar, E.S., Moudgil, T., Meyer, R.D., and Ho, D.D. (1991). Transient
deleted from the reservoir, leaving only cells specific for high levels of viremia in patients with primary human immunodefi-
rarely encountered antigens. It is therefore possible that ciency virus type 1 infection. N. Engl. J. Med. 324, 961±964.
the half-life of this compartment may be even longer Embretson, J.,Zupancic, M., Ribas, J.L., Burke, A., Racz, P., Tenner-
than the mean half-life of memory T cells in uninfected Racz, K., and Haase, A.T. (1993). Massive covert infection of helper
T lymphocytes and macrophages by HIV during the incubation pe-individuals.
riod of AIDS. Nature 362, 359±362.Taken together, these results suggest that HIV-1 can
Finkel, T.H., Tudor-Williams, G., Banda, N.K., Cotton, M.F., Curiel,establish latent infection in long-lived resting memory
T., Monks, C., Baba, T.W., Ruprecht, R.M., and Kupfer, A. (1995).CD41 T cells and that this reservoir may represent a
Apoptosis occurs predominantly in bystander cells and not in pro-
major barrier that will have to be overcome in efforts to ductively infected cells of HIV- and SIV-infected lymph nodes. Nat.
eradicate the infection with antiretroviral therapy. More Med. 1, 129±134.
optimistically, it is important to note that the compart- Finzi, D., Hermankova, M., Pierson, T., Carruth, L.M., Buck, C.,
ment is comprised of fewer than 107 cells. It is possible Chaisson, R.E., Quinn, T.C., Chadwick, K., Margolick, J., Brook-
meyer, R., et al. (1997). Identification of a reservoir for HIV-1 inthat enhancement or reconstitution of immune responses
patients on highly active antiretroviral therapy. Science 278, 1295±to HIV-1 in treated patients, including CD41 helper re-
1300.sponses, could eventually allow immunologic control of
Folks, T.M., Clouse, K.A., Justement, J., Rabson, A., Duh, E., Kehrl,viruses originating from this reservoir (Rosenberg et al.,
J.H., and Fauci, A.S. (1989). Tumor necrosis factor alpha induces
1997). expression of human immunodeficiency virus in a chronically in-
fected T-cell clone. Proc. Natl. Acad. Sci. USA 86, 2365±2368.
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